Increased level of serum HLA class I antigens in patients with systemic lupus in patients with systemic lupus erythematosus. Correlation with disease activity. 1998

A Bresciani, and G Pirozzi, and M Spera, and M L Lombardi, and L Ambrosone, and S Migliaresi, and S Ferrone, and C Manzo
Servizio di Oncologia Sperimentale C-Immunologia, Istituto Tumori Fondazione Pascale, Napoli, Italy.

The level of soluble beta2-mu-associated HLA Class I heavy chains (sHLA-I) and of soluble beta2-mu-free HLA Class I heavy chains (sHLA-FHC) was found to be significantly higher in sera from 58 patients with systemic lupus erythematosus (SLE) than in those from 82 age and sex-matched controls. The level of serum sHLA-I in patients with SLE was significantly correlated to disease activity. Western blotting analysis showed that the 44-kDa isoform represents the major component in the antigens immunoprecipitated by anti-beta2-mu mAb NAMB-1 and by anti-beta2-mu-free HLA Class I heavy chain mAb HC-10 from sera of patients with SLE. These results suggest that the increased serum levels of sHLA-I and of sHLA-FHC in patients with SLE reflect their increased shedding from cell membrane. In view of the ability of sHLA-I and of sHLA-FHC to induce apoptosis of activated T cells, it is suggested that their increased serum levels in patients with SLE is triggered by dysregulation of the immune system leading to T-cell activation. The increased serum levels of sHLA-I and of sHLA-FHC may be used by the immune system to control the pool of activated T cells by inducing apoptosis. If this possibility is proven to be correct, modulation of the serum level of sHLA-I and of sHLA-FHC may be utilized to develop strategies to treat SLE.

UI MeSH Term Description Entries
D007143 Immunoglobulin Heavy Chains The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa. Immunoglobulins, Heavy-Chain,Heavy-Chain Immunoglobulins,Ig Heavy Chains,Immunoglobulin Heavy Chain,Immunoglobulin Heavy Chain Subgroup VH-I,Immunoglobulin Heavy Chain Subgroup VH-III,Heavy Chain Immunoglobulins,Heavy Chain, Immunoglobulin,Heavy Chains, Ig,Heavy Chains, Immunoglobulin,Immunoglobulin Heavy Chain Subgroup VH I,Immunoglobulin Heavy Chain Subgroup VH III,Immunoglobulins, Heavy Chain
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015153 Blotting, Western Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes. Immunoblotting, Western,Western Blotting,Western Immunoblotting,Blot, Western,Immunoblot, Western,Western Blot,Western Immunoblot,Blots, Western,Blottings, Western,Immunoblots, Western,Immunoblottings, Western,Western Blots,Western Blottings,Western Immunoblots,Western Immunoblottings
D015395 Histocompatibility Antigens Class I Membrane glycoproteins consisting of an alpha subunit and a BETA 2-MICROGLOBULIN beta subunit. In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in determining the serological specificity of the surface antigen. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognized during GRAFT REJECTION and restrict cell-mediated lysis of virus-infected cells. Class I Antigen,Class I Antigens,Class I Histocompatibility Antigen,Class I MHC Protein,Class I Major Histocompatibility Antigen,MHC Class I Molecule,MHC-I Peptide,Class I Histocompatibility Antigens,Class I Human Antigens,Class I MHC Proteins,Class I Major Histocompatibility Antigens,Class I Major Histocompatibility Molecules,Human Class I Antigens,MHC Class I Molecules,MHC-I Molecules,MHC-I Peptides,Antigen, Class I,Antigens, Class I,I Antigen, Class,MHC I Molecules,MHC I Peptide,MHC I Peptides,Molecules, MHC-I,Peptide, MHC-I,Peptides, MHC-I

Related Publications

A Bresciani, and G Pirozzi, and M Spera, and M L Lombardi, and L Ambrosone, and S Migliaresi, and S Ferrone, and C Manzo
May 1996, Arthritis and rheumatism,
A Bresciani, and G Pirozzi, and M Spera, and M L Lombardi, and L Ambrosone, and S Migliaresi, and S Ferrone, and C Manzo
June 2001, Journal of autoimmunity,
A Bresciani, and G Pirozzi, and M Spera, and M L Lombardi, and L Ambrosone, and S Migliaresi, and S Ferrone, and C Manzo
August 1994, Human immunology,
A Bresciani, and G Pirozzi, and M Spera, and M L Lombardi, and L Ambrosone, and S Migliaresi, and S Ferrone, and C Manzo
June 1993, The Tokai journal of experimental and clinical medicine,
A Bresciani, and G Pirozzi, and M Spera, and M L Lombardi, and L Ambrosone, and S Migliaresi, and S Ferrone, and C Manzo
January 1999, Lupus,
A Bresciani, and G Pirozzi, and M Spera, and M L Lombardi, and L Ambrosone, and S Migliaresi, and S Ferrone, and C Manzo
January 1984, Terapevticheskii arkhiv,
A Bresciani, and G Pirozzi, and M Spera, and M L Lombardi, and L Ambrosone, and S Migliaresi, and S Ferrone, and C Manzo
May 1994, Medicina clinica,
A Bresciani, and G Pirozzi, and M Spera, and M L Lombardi, and L Ambrosone, and S Migliaresi, and S Ferrone, and C Manzo
January 1994, Scandinavian journal of rheumatology,
A Bresciani, and G Pirozzi, and M Spera, and M L Lombardi, and L Ambrosone, and S Migliaresi, and S Ferrone, and C Manzo
October 1994, Lupus,
A Bresciani, and G Pirozzi, and M Spera, and M L Lombardi, and L Ambrosone, and S Migliaresi, and S Ferrone, and C Manzo
December 1997, Human immunology,
Copied contents to your clipboard!